| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
43,700,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Prelude Therapeutics is a clinical-stage oncology company built on a foundation of drug discovery to deliver precision cancer medicines to underserved patients. Co.'s primary candidates are designed to be oral, potent and selective inhibitors of protein arginine methyltransferase 5 (PRMT5). PRT811, Co.'s second clinical candidate, is a PRMT5 inhibitor that it has optimized for high brain exposure. PRT1419, Co.'s third clinical candidate, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527, Co.'s fourth clinical candidate, is designed to be a potent and selective Cyclin-dependent kinase 9 inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
834,521 |
1,044,484 |
1,044,484 |
| Total Buy Value |
$0 |
$581,057 |
$806,603 |
$806,603 |
| Total People Bought |
0 |
2 |
3 |
3 |
| Total Buy Transactions |
0 |
6 |
13 |
13 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Huang Jane |
President, CMO |
• – – |
2025-04-04 |
4 |
D |
$0.68 |
$2,265 |
D/D |
(3,355) |
74,877 |
|
- |
|
| Huang Jane |
President, CMO |
• – – |
2025-04-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,375 |
78,232 |
|
- |
|
| Combs Andrew |
Chief Chemistry Officer |
• – – |
2025-03-25 |
4 |
B |
$0.69 |
$69,250 |
D/D |
100,000 |
480,123 |
0.01 |
- |
|
| Vaddi Krishna |
CEO |
• • – |
2025-03-25 |
4 |
B |
$0.69 |
$467,438 |
D/D |
675,000 |
1,999,296 |
0.01 |
- |
|
| Vaddi Krishna |
CEO |
• • – |
2025-03-21 |
4 |
B |
$0.73 |
$10,959 |
D/D |
15,000 |
1,324,296 |
0.01 |
- |
|
| Vaddi Krishna |
CEO |
• • – |
2025-03-20 |
4 |
B |
$0.73 |
$3,950 |
D/D |
5,416 |
1,309,296 |
0.01 |
- |
|
| Vaddi Krishna |
CEO |
• • – |
2025-03-17 |
4 |
B |
$0.75 |
$6,829 |
D/D |
9,106 |
1,303,880 |
0.01 |
- |
|
| Vaddi Krishna |
CEO |
• • – |
2025-03-14 |
4 |
B |
$0.75 |
$22,631 |
D/D |
29,999 |
1,294,774 |
0.01 |
- |
|
| Huang Jane |
President, CMO |
• – – |
2025-01-04 |
4 |
D |
$1.39 |
$5,364 |
D/D |
(3,859) |
68,857 |
|
- |
|
| Huang Jane |
President, CMO |
• – – |
2025-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,375 |
72,716 |
|
- |
|
| Vaddi Krishna |
CEO |
• • – |
2024-12-31 |
4 |
B |
$1.21 |
$6,044 |
I/I |
5,000 |
142,553 |
0.01 |
- |
|
| Vaddi Krishna |
CEO |
• • – |
2024-12-30 |
4 |
B |
$1.20 |
$12,000 |
I/I |
10,000 |
137,553 |
0.01 |
- |
|
| Combs Andrew |
Chief Chemistry Officer |
• – – |
2024-12-23 |
4 |
B |
$1.37 |
$82,002 |
D/D |
60,000 |
377,623 |
0.01 |
- |
|
| Combs Andrew |
Chief Chemistry Officer |
• – – |
2024-12-20 |
4 |
B |
$1.15 |
$3,536 |
D/D |
3,075 |
317,623 |
0.01 |
- |
|
| Vaddi Krishna |
CEO |
• • – |
2024-12-19 |
4 |
B |
$0.89 |
$6,116 |
I/I |
6,888 |
127,553 |
0.01 |
- |
|
| Lim Bryant David |
CLO, Interim CFO, Corp Sec. |
• – – |
2024-12-19 |
4 |
B |
$0.91 |
$22,638 |
D/D |
25,000 |
27,400 |
0.01 |
- |
|
| Vaddi Krishna |
CEO |
• • – |
2024-12-18 |
4 |
B |
$0.93 |
$93,210 |
D/D |
100,000 |
1,167,275 |
0.01 |
- |
|
| Huang Jane |
President, CMO |
• – – |
2024-10-04 |
4 |
D |
$2.00 |
$6,698 |
D/D |
(3,349) |
63,341 |
|
- |
|
| Huang Jane |
President, CMO |
• – – |
2024-10-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,375 |
66,690 |
|
- |
|
| Huang Jane |
President, CMO |
• – – |
2024-07-04 |
4 |
D |
$3.60 |
$12,049 |
D/D |
(3,347) |
57,315 |
|
- |
|
| Huang Jane |
President, CMO |
• – – |
2024-07-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,375 |
60,662 |
|
- |
|
| Huang Jane |
President, CMO |
• – – |
2024-04-04 |
4 |
D |
$4.74 |
$15,865 |
D/D |
(3,347) |
51,287 |
|
- |
|
| Huang Jane |
President, CMO |
• – – |
2024-04-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,375 |
54,634 |
|
- |
|
| Huang Jane |
President, CMO |
• – – |
2024-01-04 |
4 |
D |
$3.77 |
$14,492 |
D/D |
(3,844) |
45,259 |
|
- |
|
| Huang Jane |
President, CMO |
• – – |
2024-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,375 |
49,103 |
|
- |
|
121 Records found
|
|
Page 1 of 5 |
|
|
